Lantern Pharma ($LTRN) just launched ZetaOmics: Is the market overlooking its AI platform?

Lantern just launched ZetaOmics, the computational biology module of its withZeta.ai platform. Unlike a standard LLM chatbot, it’s designed as an autonomous “computational biologist” that can perform end-to-end multi-omics and bioinformatics analyses from natural language queries. The company says it integrates 14 specialized tools and more than 615,000 curated cancer samples, with an early-access rollout now underway.

What’s interesting to me is that this wasn’t announced out of nowhere:

- April: withZeta launched commercially.
- May: ZetaOmics appeared on the public roadmap.
- July: ZetaOmics moved from roadmap to early access.

Near-term catalysts:

- withZeta commercialization and first enterprise customers
- additional LP-300 HARMONIC updates
- planned LP-184 Phase 1b/2 expansion
- further progress on the planned withZeta business spinout.

With a market cap of only ~$40–50M, do you think the market is assigning any value to the AI platform, or is it still pricing Lantern purely as a small clinical-stage biotech?